GLENMARK PHARMACEUTICALS
Back to Cashflow Statement
|
GLENMARK PHARMACEUTICALS Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Cash Flow from Financing Activities | ₹787 Cr | ₹-3,906 Cr | ₹-77 Cr | ₹-520 Cr | ₹-442 Cr |
What is the latest Cash Flow from Financing Activities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Cash Flow from Financing Activities |
|---|---|
| Mar2025 | ₹787 Cr |
| Mar2024 | ₹-3,906 Cr |
| Mar2023 | ₹-77 Cr |
| Mar2022 | ₹-520 Cr |
| Mar2021 | ₹-442 Cr |
How is Cash Flow from Financing Activities of GLENMARK PHARMACEUTICALS Trending?
| Years | Cash Flow from Financing Activities | % Change | |
|---|---|---|---|
| Mar2025 | ₹787 Cr | Positive | |
| Mar2024 | ₹-3,906 Cr | Negative | |
| Mar2023 | ₹-77 Cr | Negative | |
| Mar2022 | ₹-520 Cr | Negative | |
| Mar2021 | ₹-442 Cr | - | |
Compare Cash Flow from Financing Activities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹61,657.9 Cr | -0.6% | -0.1% | 0.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹474,396.0 Cr | 1.8% | 5.6% | 16.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹196,990.0 Cr | 0.5% | 13.1% | 10.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹186,354.0 Cr | -2.7% | 5.1% | 42.4% | Stock Analytics | |
| CIPLA | ₹116,705.0 Cr | 2.1% | -0.6% | -4.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹94,790.0 Cr | -4% | -17.5% | -8.6% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | -0.6% |
-0.1% |
0.5% |
| SENSEX | -0.9% |
-0.4% |
-6.1% |
You may also like the below Video Courses